Listen
QALSODY (tofersen) - Amyotrophic lateral sclerosis (ALS)
Opinions on drugs -
Posted on
Nov 28 2024
Reason for request
First listing
Summary of opinion
Unfavourable opinion for reimbursement in the treatment of adults with amyotrophic lateral sclerosis (ALS), associated with a mutation in the superoxide dismutase 1 (SOD1) gene.
Clinical Benefit
| Insufficient |
The Committee deems that the clinical benefit of QALSODY (tofersen) is insufficient to justify its public funding in the MA indication. |
Clinical Added Value
| Not applicable |
Documents
English version
Contact Us
Évaluation des médicaments
